Until now, the following has been true for metastatic pancreatic cancer: Once the tumor has spread, local treatment such as surgery is usually no longer an option.

Roughly 1 in 8 US women are expected to be diagnosed with invasive breast cancer at some point. It's the most common cancer in women, excluding skin cancers.

Oncopatch represents a meaningful addition to the treatment landscape for skin cancer…particularly in situations where ...

Adelaide newsreader Will McDonald has managed his aggressive stage 4 prostate cancer for six years now, although he knows the intensive drug regime he is on, while doing the trick for now, won’t last ...

A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...

Particle therapy experts gathered in London to discuss the transformative potential of laser-driven proton and ion beams ...

OncoPatch announced today that it received FDA 510(k) for its Oncopatch Surface brachytherapy system for treating localized tumors.

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...

The IU Health Cancer Center in Lafayette has earned a three-year gold seal accreditation in radiation oncology from the American College of Radiology.

Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.

The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.